AlphAIalphai — Financial news for AI agents
BenzingaDEC 164 min read$HSIC

Top 2 Health Care Stocks That May Keep You Up At Night In December

This article identifies two healthcare stocks, Henry Schein (HSIC) and Avidity Biosciences (RNA), that might concern investors due to their overbought status indicated by a high Relative Strength Index (RSI). Avidity Biosciences recently missed analyst consensus on quarterly losses but beat sales estimates and announced a merger agreement with Novartis, while Henry Schein received an Overweight rating from Barclays. Investors are advised to consider momentum as a key trading criterion when evaluating these stocks.

Original reporting
Benzinga · Avi Kapoor
Published Dec 16, 2025, 1:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Dec 16, 2025, 2:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Top 2 Health Care Stocks That May Keep You Up At Night In December — source image
Source · Benzinga
Decision brief

The 30-second read

$HSICNeutralMed
01

Why it matters

Technical overbought conditions may lead to short-term corrections, but fundamental developments like analyst upgrades and mergers could support longer-term stability.

02

Market read

Healthcare stocks are exhibiting overbought technical signals amid positive fundamental news, suggesting a cautious approach for traders.

03

What to watch

Broader market momentum and sector rotation could override technical signals, leading to continued gains despite overbought indicators.

Timing: short-term (next 1-4 weeks)

Background

The article highlights recent technical overbought signals in healthcare stocks, specifically HSIC and RNA, amid mixed quarterly results and significant corporate news.

Company-level read

Ticker impact

$HSICNeutralMedium confidence
Context

Healthcare sector, overbought status indicated by high RSI, recent positive analyst rating from Barclays.

Expected impact

Potential short-term price correction of 3-5% due to overbought conditions, followed by possible stabilization or rebound depending on broader market trends.

Evidence & confidence

High RSI levels often precede short-term pullbacks, but positive analyst ratings and sector fundamentals support continued long-term stability.

$RNABullishMedium confidence
Context

Avidity Biosciences (RNA) recently missed quarterly earnings consensus but beat sales estimates, announced a merger with Novartis, and has a somewhat bullish sentiment from market data.

Expected impact

Possible short-term volatility with a slight upward bias (+2-4%) driven by merger news, contingent on broader market conditions.

Evidence & confidence

Merger announcement can boost stock price, but earnings miss introduces uncertainty. Overall, the news is favorable but warrants cautious optimism.

Market effects

Sector

Potential sector-wide caution due to overbought conditions in healthcare stocks, which may lead to short-term profit-taking.

Regional

Limited; primarily US-based stocks with minimal immediate regional effects.

Global

Moderate; healthcare sector movements can influence global biotech and pharma markets, especially if broader indices are affected.

Counterpoint

What could challenge this read

HSIC's strong fundamentals and analyst support suggest the overbought condition may be a temporary pullback within an ongoing uptrend.

Key entities

  • Company
    Henry Schein

    A global healthcare solutions company.

  • Company
    Avidity Biosciences

    A biotech firm specializing in RNA-based therapeutics.

  • Company
    Novartis

    A multinational pharmaceutical corporation involved in the merger with RNA.

Read at source← All news

Related articles

AUG 13
$RNAMedAI 8/10

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

Atrium Therapeutics (Nasdaq: RNA) reported Q2 2026 results for the quarter ended June 30. FDA cleared its IND for ATR 1072 and it launched the Corventis Phase 1/2 trial for PRKAG2 syndrome. Atrium also received a $15 million second milestone payment from Bristol Myers Squibb. Q2 collaboration revenue was $3.0M, R&D $15.3M, G&A $10.3M, cash $263.9M.

prnewswire.com6 min
AUG 13
$RNAMed

Atrium Therapeutics, Inc. (RNA): Results of Operations and Financial Condition

Atrium Therapeutics, Inc. (RNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d149126dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atrium Therapeutics Reports Second Quarter 2026 Financial Results — IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome — — Achieved second milestone payment under global cardiovascular col

SEC EDGAR 8-K4 min
AUG 11
$HSICMedAI 8/10

Henry Schein (HSIC) Q2 2026 Earnings Call Transcript

Henry Schein (HSIC) reported Q2 2026 net sales of $3.5 billion, up 6.7%, and non-GAAP diluted EPS of $1.27. GAAP diluted EPS was $0.82. The company raised 2026 guidance, including non-GAAP EPS to $5.29 to $5.39 and sales growth to 4.5% to 5.5%, and approved $200 million in share repurchases.

fool.com6 min
AUG 7
$HSICMed

Henry Schein Recasts Its Future Around AI, Simpler Leadership and Faster Execution

Henry Schein Inc. outlined a transformation focused on AI, simpler leadership, and faster execution in its first earnings report under CEO Fred Lowery. The company reported Q2 net sales of $3.46B (+6.7%) and net income of $94M (+9.3%), raised its 2026 sales outlook to 4.5% to 5.5%, and announced a leadership reorganization integrating supply chain and distribution. It targets $200M+ operating improvements.

distributionstrategy.com7 min
AUG 6
$HSICMedAI 8/10

Henry Schein, Inc. Q2 2026 Earnings Call Summary

Henry Schein reported Q2 2026 progress including faster internal local-currency sales growth, driven by dental merchandise market-share gains and higher technology platform share. The company raised full-year 2026 sales growth guidance to 4.5% to 5.5% and expects $125 million operating income improvement run rate by end-2026. Restructuring expenses were $29 million.

yahoo.com6 min
AUG 4
$HSICMedAI 8/10

Henry Schein (NASDAQ:HSIC) Surprises With Q2 CY2026 Sales

Henry Schein (NASDAQ:HSIC) reported Q2 CY2026 results with revenue up 6.7% year on year to $3.46 billion, exceeding Wall Street estimates by 2.6%, according to the company. Non-GAAP adjusted EPS was $1.27, up from $1.10, beating consensus by 2.5%. Adjusted operating margin was 5.3%. Analysts expect revenue growth of 2.9% over the next 12 months.

financialcontent.com3 min